DK2288727T3 - Prædiktorer for patientrespons på behandling med EGF-receptorinhibitorer - Google Patents

Prædiktorer for patientrespons på behandling med EGF-receptorinhibitorer

Info

Publication number
DK2288727T3
DK2288727T3 DK09747492.8T DK09747492T DK2288727T3 DK 2288727 T3 DK2288727 T3 DK 2288727T3 DK 09747492 T DK09747492 T DK 09747492T DK 2288727 T3 DK2288727 T3 DK 2288727T3
Authority
DK
Denmark
Prior art keywords
predictors
treatment
egf receptor
receptor inhibitors
patient response
Prior art date
Application number
DK09747492.8T
Other languages
English (en)
Inventor
Joffre B Baker
Drew Watson
Tara Maddala
Steven Shak
David J Mauro
Shirin K Ford
Original Assignee
Genomic Health Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc, Bristol Myers Squibb Co filed Critical Genomic Health Inc
Application granted granted Critical
Publication of DK2288727T3 publication Critical patent/DK2288727T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09747492.8T 2008-05-14 2009-05-13 Prædiktorer for patientrespons på behandling med EGF-receptorinhibitorer DK2288727T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12781608P 2008-05-14 2008-05-14
PCT/US2009/043823 WO2009140409A1 (en) 2008-05-14 2009-05-13 Predictors of patient response to treatment with egf receptor inhibitors

Publications (1)

Publication Number Publication Date
DK2288727T3 true DK2288727T3 (da) 2013-10-21

Family

ID=41319044

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09747492.8T DK2288727T3 (da) 2008-05-14 2009-05-13 Prædiktorer for patientrespons på behandling med EGF-receptorinhibitorer

Country Status (9)

Country Link
US (2) US8273534B2 (da)
EP (2) EP2615183B1 (da)
AU (1) AU2009246398A1 (da)
CA (1) CA2723984A1 (da)
DK (1) DK2288727T3 (da)
ES (1) ES2430590T3 (da)
HK (1) HK1154054A1 (da)
NZ (3) NZ610482A (da)
WO (1) WO2009140409A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4606879B2 (ja) 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
WO2010127322A1 (en) * 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
JP2012529895A (ja) * 2009-06-19 2012-11-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｅｇｆｒ抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法
US20130302321A1 (en) * 2010-09-28 2013-11-14 Agendia N.V. Methods and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction Pathways
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012170715A1 (en) * 2011-06-07 2012-12-13 Caris Mpi, Inc. Molecular profiling for cancer
WO2013052480A1 (en) * 2011-10-03 2013-04-11 The Board Of Regents Of The University Of Texas System Marker-based prognostic risk score in colon cancer
EP2802673B1 (en) * 2012-01-09 2019-07-03 Oslo Universitetssykehus HF Methods and biomarkers for analysis of colorectal cancer
CN105407913A (zh) * 2012-07-31 2016-03-16 中美冠科生物技术（太仓）有限公司 用于鉴定可用抗egfr药物治疗的食管癌患者的生物标志物
WO2014028222A1 (en) * 2012-07-31 2014-02-20 Crown Bioscience, Inc. Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
WO2014071226A1 (en) * 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
GB201223025D0 (en) * 2012-12-20 2013-02-06 Medizinische Universitaet Graz Prediction of the treatment response to an anti-EGFR molecule in colorectal cancer patients
BR112016020897A2 (pt) * 2014-03-11 2018-01-23 Council Queensland Inst Medical Res ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento?
US20160024585A1 (en) * 2014-05-02 2016-01-28 Duke University Methods of predicting responsiveness of a cancer to an agent and methods of determining a prognosis for a cancer patient
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
FR3037403A1 (fr) * 2015-06-12 2016-12-16 Centre Leon Berard Procede de prediction de la sensibilite d'une tumeur gastro-intestinale a un traitement inhibiteur
CN106148533B (zh) * 2016-07-28 2019-06-11 北京泱深生物信息技术有限公司 用于食管鳞癌诊治的标志物
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
WO2020080871A2 (ko) * 2018-10-18 2020-04-23 (주)신테카바이오 암 약물 반응성 판단을 위한 바이오 마커 조성물, 바이오 마커 조성물을 이용한 암 약물 반응성 판단 방법 및 암 약물 반응성 판단을 위한 바이오 마커 조성물 검출용 진단칩

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
JPH09508800A (ja) 1994-02-14 1997-09-09 スミスクライン・ビーチャム・コーポレイション 差次的発現遺伝子の同定法
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
EP1265582A2 (en) * 1999-09-29 2002-12-18 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
JP2005519624A (ja) * 2002-03-13 2005-07-07 ジェノミック ヘルス， インコーポレイテッド 生検腫瘍組織での遺伝子発現プロファイリング
CA2478640A1 (en) * 2002-03-13 2003-09-18 F. Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
JP4606879B2 (ja) * 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
EP1597391B1 (en) * 2003-02-20 2008-10-29 Genomic Health, Inc. Use of intronic rna to measure gene expression
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
CN101193905B (zh) 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
US20070009267A1 (en) * 2005-06-22 2007-01-11 Crews Darren S Driving a laser using an electrical link driver
JP2008546421A (ja) 2005-06-28 2008-12-25 ジェネンテック・インコーポレーテッド Ｅｇｆｒおよびｋｒａｓ変異
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
ES2370054T3 (es) 2005-08-24 2011-12-12 Bristol-Myers Squibb Company Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico.
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
JP5297202B2 (ja) 2006-01-11 2013-09-25 ジェノミック ヘルス， インコーポレイテッド 結腸直腸癌の予後のための遺伝子発現マーカー
WO2008115419A2 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009114836A1 (en) * 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2010127322A1 (en) * 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy

Also Published As

Publication number Publication date
HK1154054A1 (en) 2012-04-20
EP2615183B1 (en) 2014-10-08
AU2009246398A1 (en) 2009-11-19
EP2288727A1 (en) 2011-03-02
EP2288727A4 (en) 2011-09-14
NZ610482A (en) 2014-08-29
CA2723984A1 (en) 2009-11-19
EP2615183A1 (en) 2013-07-17
US20090298701A1 (en) 2009-12-03
EP2288727B1 (en) 2013-07-10
WO2009140409A1 (en) 2009-11-19
NZ589143A (en) 2012-02-24
US8273534B2 (en) 2012-09-25
NZ597292A (en) 2013-06-28
ES2430590T3 (es) 2013-11-21
US20120270228A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
DK2288727T3 (da) Prædiktorer for patientrespons på behandling med EGF-receptorinhibitorer
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
SMT201600281B (it) Trattamento di disturbi correlati a bdnf usando laquinimod
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
DK2321430T3 (da) Fremgangsmåde til at evaluere oral cancer riskiko hos mennesker
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
BRPI1014775A2 (pt) tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta
HK1154575A1 (zh) 用於治療增生性疾病的不對稱吡咯並苯並二氮雜卓二聚物
HK1177438A1 (en) Device used for treatment of rhinitis by biostimulative illumination
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK3284820T3 (da) Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger
BRPI1014688A2 (pt) aplicações terapêuticas de derivados de quinazolinadiona
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
SMT201600156B (it) Trattamento dell’osteoartrite
FR2930723B1 (fr) Orthese de cheville
CU23884B1 (es) Derivados de dibenzotiazepina
DK2424538T3 (da) Anvendelse af allopurinol til behandling af hånd-fod-hudreaktion
SMT201500123B (it) Dosaggio unitario di apadenoson
ZA201108702B (en) Piperidine derivatives useful for treatment of diabetes
DK2509584T3 (da) Farmaceutisk sammensætning til behandling af forbrændinger i huden
DK2419728T3 (da) Biomarkør til at overvåge patienter
IL210558A0 (en) Treatment of anxiety disorders